Chimagen Biosciences Announces Sale of CMG1A46 to GSK
October 31, 2024
October 31, 2024
PALO ALTO, California, Oct. 31 -- Cooley, a law firm, issued the following news release:
Palo Alto and Shanghai - October 29, 2024 - Cooley advised Chimagen Biosciences, a privately held biotechnology company, on its agreement to sell CMG1A46, a clinical-stage dual CD19 and CD20-targeted T-cell engager (TCE), to GSK, a global biopharma company. Under the terms of the agreement, GSK will pay $300 million upfront to acquire full global rights to CMG1A46, and Chimagen will be eligible . . .
Palo Alto and Shanghai - October 29, 2024 - Cooley advised Chimagen Biosciences, a privately held biotechnology company, on its agreement to sell CMG1A46, a clinical-stage dual CD19 and CD20-targeted T-cell engager (TCE), to GSK, a global biopharma company. Under the terms of the agreement, GSK will pay $300 million upfront to acquire full global rights to CMG1A46, and Chimagen will be eligible . . .